CN1440385A - 用于治疗艾滋病的吡咯衍生物 - Google Patents

用于治疗艾滋病的吡咯衍生物 Download PDF

Info

Publication number
CN1440385A
CN1440385A CN01812290A CN01812290A CN1440385A CN 1440385 A CN1440385 A CN 1440385A CN 01812290 A CN01812290 A CN 01812290A CN 01812290 A CN01812290 A CN 01812290A CN 1440385 A CN1440385 A CN 1440385A
Authority
CN
China
Prior art keywords
methyl
pyridyl
pyrrole
isopropyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01812290A
Other languages
English (en)
Chinese (zh)
Inventor
B·W·迪莫克
P·S·约内斯
J·H·梅里特
M·J·帕拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1440385A publication Critical patent/CN1440385A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN01812290A 2000-07-04 2001-04-30 用于治疗艾滋病的吡咯衍生物 Pending CN1440385A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0016453.3 2000-07-04
GBGB0016453.3A GB0016453D0 (en) 2000-07-04 2000-07-04 Pyrrole derivatives

Publications (1)

Publication Number Publication Date
CN1440385A true CN1440385A (zh) 2003-09-03

Family

ID=9895031

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01812290A Pending CN1440385A (zh) 2000-07-04 2001-04-30 用于治疗艾滋病的吡咯衍生物

Country Status (17)

Country Link
US (1) US6737429B2 (cg-RX-API-DMAC7.html)
EP (1) EP1301481A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004502674A (cg-RX-API-DMAC7.html)
KR (1) KR100549884B1 (cg-RX-API-DMAC7.html)
CN (1) CN1440385A (cg-RX-API-DMAC7.html)
AR (1) AR028602A1 (cg-RX-API-DMAC7.html)
AU (2) AU6387401A (cg-RX-API-DMAC7.html)
BR (1) BR0112241A (cg-RX-API-DMAC7.html)
CA (1) CA2412270A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP014109A (cg-RX-API-DMAC7.html)
GB (1) GB0016453D0 (cg-RX-API-DMAC7.html)
GT (1) GT200100111A (cg-RX-API-DMAC7.html)
MX (1) MXPA02012409A (cg-RX-API-DMAC7.html)
PA (1) PA8516201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020269A1 (cg-RX-API-DMAC7.html)
UY (1) UY26720A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002002524A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081387A1 (zh) * 2009-01-13 2010-07-22 中国人民解放军军事医学科学院毒物药物研究所 N-取代苯基-3-甲烯杂环芳烃-2，5-二甲基吡咯类化合物及其抗hiv/aids的应用
CN101837125A (zh) * 2003-12-26 2010-09-22 萩原正敏 Sr蛋白质的磷酸化控制方法以及以包含sr蛋白质活性控制剂的试剂为有效成分的抗病毒剂

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405849A1 (en) * 2002-10-04 2004-04-07 Corning Incorporated Halogenated styrene compounds and low-absorption-loss polymers obtainable therefrom
JP5173192B2 (ja) 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
TW200628446A (en) * 2004-12-14 2006-08-16 Takeda Pharmaceuticals Co Substituted pyrrole derivative
WO2006072833A1 (en) * 2005-01-06 2006-07-13 Pfizer Limited Imidazole derivatives as enzyme reverse transcriptase modulators
UA94424C2 (en) 2005-08-30 2011-05-10 Такеда Фармасьютикал Компани Лимитед 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
EP2076492A4 (en) * 2006-10-06 2010-12-22 Merck Sharp & Dohme NON-NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS
CA2669675A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. Combination of er.alpha.+ ligands and histone deacetylase inhibitors for the treatment of cancer
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2009015180A2 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009050977A1 (en) * 2007-10-16 2009-04-23 Nikon Corporation Illumination optical system, exposure apparatus, and device manufacturing method
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
DK2318390T3 (da) 2008-08-27 2013-07-08 Takeda Pharmaceutical Pyrrolforbindelser
GB0823001D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Thiophene,furan and pyrrole derivatives with plant growth regulating properties
EP4061360A4 (en) * 2019-11-19 2023-07-05 New York Blood Center, Inc. SUBSTITUTED HETEROCYCLIC COMPOUNDS SHOWING THERAPEUTIC ACTIVITY AGAINST HIV

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644631A (en) * 1969-05-13 1972-02-22 Endo Lab Therapeutic methods utilizing aryl pyrrol-3-yl ketones
US4282242A (en) * 1980-03-07 1981-08-04 Pfizer Inc. Antidiabetic pyrrolecarboxylic acids
US4347186A (en) * 1980-10-20 1982-08-31 Syntex (U.S.A.) Inc. Process for preparing 5-aroyl 1,2-dihydro-3-H pyrrolo[1,2-a]pyrrole-1-carboxylic acids and novel intermediates therein
ATE187451T1 (de) * 1992-12-17 1999-12-15 Pfizer Substituierte pyrazole als crf antagonisten
US5968944A (en) * 1994-06-06 1999-10-19 Pfizer Inc. Substituted pyrazoles as corticotropin-releasing factor (CRF) antagonists
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
EP0912548A1 (en) * 1996-07-11 1999-05-06 Pfizer Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
DE19963174A1 (de) * 1999-12-27 2001-07-12 Gruenenthal Gmbh Substituierte Pyrrol-Mannichbasen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101837125A (zh) * 2003-12-26 2010-09-22 萩原正敏 Sr蛋白质的磷酸化控制方法以及以包含sr蛋白质活性控制剂的试剂为有效成分的抗病毒剂
WO2010081387A1 (zh) * 2009-01-13 2010-07-22 中国人民解放军军事医学科学院毒物药物研究所 N-取代苯基-3-甲烯杂环芳烃-2，5-二甲基吡咯类化合物及其抗hiv/aids的应用

Also Published As

Publication number Publication date
MXPA02012409A (es) 2003-04-25
US6737429B2 (en) 2004-05-18
BR0112241A (pt) 2003-06-24
CA2412270A1 (en) 2002-01-10
GB0016453D0 (en) 2000-08-23
AR028602A1 (es) 2003-05-14
US20020032221A1 (en) 2002-03-14
PE20020269A1 (es) 2002-04-08
AU6387401A (en) 2002-01-14
GT200100111A (es) 2002-03-18
WO2002002524A1 (en) 2002-01-10
UY26720A1 (es) 2001-11-30
PA8516201A1 (es) 2002-07-30
KR20030014321A (ko) 2003-02-15
AU2001263874B2 (en) 2006-10-19
KR100549884B1 (ko) 2006-02-06
ECSP014109A (es) 2002-02-25
JP2004502674A (ja) 2004-01-29
EP1301481A1 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
CN1051544C (zh) 苯磺酰胺衍生物及其制备方法
CN100341862C (zh) 噻唑烷衍生物及其医药用途
CN1192021C (zh) 作为阿片受体配体的3－氮杂二环[3.1.0]己烷衍生物
CN1301973C (zh) 杂环衍生物及医药品
CN1440385A (zh) 用于治疗艾滋病的吡咯衍生物
CN1653047A (zh) 抗炎症药物单环芳酰吡啶酮
CN1374953A (zh) 含氮的6－员芳香环化合物
CN1623984A (zh) 稠环化合物及其药物用途
CN1191239C (zh) 用于治疗病毒性疾病的吡唑衍生物
CN1058779A (zh) 喹诺酮衍生物和含有该化合物的药物组合物
CN1214339A (zh) 吡唑衍生物、其制备方法和在药物中的应用
CN1665789A (zh) 二氨基嘧啶酰胺衍生物
CN1561216A (zh) 新化合物
CN1056879A (zh) 吡咯衍生物及其制备方法
CN1234031A (zh) 吲唑衍生物及其作为磷酸二酯酶(pde)iv型和肿瘤坏死因子(tnf)产生的抑制剂的应用
CN1198804C (zh) 酰胺化合物及其用途
CN1505628A (zh) 用于治疗由有害细胞因子活性引起的疾病的三唑化合物
CN1495169A (zh) 吡啶-3-羧酸衍生物
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1582277A (zh) 用作糖原合酶激酶3β抑制剂的酰胺衍生物
CN1688577A (zh) 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物
CN1049219C (zh) 具有内皮素拮抗活性的芳香杂环并环戊烯衍生物
CN1529593A (zh) 作为前列腺素类化合物激动剂的2-吡咯烷酮衍生物
CN1294126C (zh) N－苯基芳基磺酰胺化合物、包括该化合物作为活性成分的药物组合物、该化合物的合成中间体及其制备方法
CN1933830A (zh) 吲哚衍生物和其作为激酶抑制剂特别是ikk2抑制剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication